key: cord-0796142-bixbwjua
authors: O’Horo, John; Challener, Douglas W.; Anderson, Ryan J.; Arndt, Richard F.; Ausman, Sara E.; Hall, Scott T.; Heyliger, Alexander; Kennedy, Brian D.; Sweeten, Perry W.; Ganesh, Ravindra; Razonable, Raymund R.
title: Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease-2019
date: 2022-02-23
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2022.02.009
sha: 56bd4e74dd8d04a907b5bf1700f675546ae04362
doc_id: 796142
cord_uid: bixbwjua

Bamlanivimab-etesevimab and casirivimab-imdevimab are authorized by the US FDA for emergency treatment of mild to moderate COVID-19 in high-risk persons. There has been no study comparing their clinical efficacy. In this retrospective study of 681 patients with mild to moderate COVID-19 during a period dominated by SARS-CoV-2 wild-type and alpha variants, 25 patients (3.67%) progressed to develop severe outcome requiring hospitalization and oxygen supplementation within 30 days after monoclonal antibody infusion. Severe outcome was significantly higher among 181 patients who were treated with casirivimab-imdevimab when compared to 500 patients who received bamlanivimab-etesevimab (6.7% vs. 2.6%, p=0.01). Casirivimab-imdevimab had higher odds of severe outcomes when compared to bamlanivimab-etesevimab (Odds Ratio: 2.67, 95% confidence interval, 1.17-6.06). The demographic and clinical characteristics, and the time to monoclonal antibody infusion, of the two treatment cohorts were not significantly different. The reason behind this significant difference in the clinical outcomes is unclear, but our observations emphasize potential efficacy differences among anti-spike monoclonal antibodies against COVID-19. Further clinical studies using larger cohort of patients are needed to confirm or refute these observations.

Monoclonal antibodies directed against the receptor-binding domain of the spike protein of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have received emergency use authorization (EUA) from the United States (US) Food and Drug Administration (FDA) for treatment of high-risk patients with mild to moderate coronavirus disease-2019 (COVID-19). 1, 2 Randomized clinical trials have demonstrated that these anti-spike monoclonal antibody therapies were associated with a more rapid decline in viral load as well as a reduction in rates of medically attended visits and hospitalizations. [3] [4] [5] Bamlanivimab (Eli Lilly, Indianapolis) monotherapy was the first to receive EUA in November 2020. 1 While real-world experience with the use of bamlanivimab monotherapy was favorable, with significant reductions in hospitalization, intensive care unit (ICU) admission, and mortality among bamlanivimab-treated patients 6 , the emergence of SARS-CoV-2 variants of concern (mainly SARS-CoV-2 B.1.351 [beta] and P. 1 [gamma] variants) led to the revocation of its EUA as monotherapy in February 2021. 7 At that time, the US FDA authorized the use of bamlanivimab only if it was given in combination with etesevimab (Eli Lilly, Indianapolis). 4, 7 In a randomized controlled trial, the bamlanivimab-etesevimab combination resulted in a significant reduction in hospitalization compared to bamlanivimab monotherapy. 4 Casirivimab-imdevimab (Regeneron, New York), another anti-spike monoclonal antibody combination, received EUA in November 2020. 2 In a randomized trial, casirivimab-imdevimab was significantly associated with a more rapid decline in viral load when compared to placebo. 2 A retrospective study reported a significant reduction in hospitalization rates among patients J o u r n a l P r e -p r o o f who received casirivimab-imdevimab compared to propensity-matched untreated patients with mild to moderate COVID-19 8 .

There are no studies comparing the clinical efficacy of bamlanivimab-etesevimab and casirivimab-imdevimab. In this study, we sought to assess differences in clinical efficacy by comparing the rates of severe outcomes among high-risk patients treated with bamlanivimabetesevimab or casirivimab-imdevimab for mild to moderate COVID-19 during the period prior to the surge of SARS-CoV-2 Delta and Omicron variants of concern.

Mayo Clinic is an integrated healthcare delivery network serving over 1 million patients each year across southern Minnesota, northeastern Iowa, western Wisconsin, and the metropolitan areas of Jacksonville, Florida, and Phoenix, Arizona. On November 7, 2020, Mayo Clinic established its Monoclonal Antibody Treatment (MATRx) Program to administer antispike monoclonal antibodies to patients at high risk of severe disease in an attempt to mitigate the risk of disease progression and hospitalization. The MATRx program, protocols, and procedures have been described previously 9 .

For this study, only patients treated in Minnesota and Wisconsin were included. By limiting the geography, we could directly compare the efficacy of these two monoclonal antibody products given similar circulating variants in the community. At the time of this study, the predominant circulating variants were SARS-CoV2 wild-type and alpha (B.1.1.7 lineage) J o u r n a l P r e -p r o o f variants, while the proportions of SARS-CoV-2 beta (B.1.351 lineage) and gamma (P.1 lineage) variants were low, allowing the use of both monoclonal antibody products interchangeably without concerns for viral resistance. In contrast, the proportion of the resistant viral variants circulating in our clinic sites in Florida and Arizona was above 5%, which prevented the use of bamlanivimab-etesevimab in those sites.

This was a retrospective study among adult patients, ≥18 years, who were identified from the Mayo Clinic electronic health records (EHR) during the period when bamlanivimabetesevimab or casirivimab-imdevimab were simultaneously authorized for use (February 9, 2021 -June 25, 2021). Bamlanivimab-etesevimab was authorized for emergency use on February 9, 2021, but its distribution was paused on June 25, 2021 due to the emergence of resistant variants of concern. Casirivimab-imdevimab, on the other hand, has been authorized for use continuously since it was first authorized for emergency use in November 2020, as it has retained activity against all known variants of concern 2 . All patients with mild to moderate COVID-19 treated with anti-spike monoclonal antibodies during the study period were included in this study. The population was divided into two cohorts based on the specific monoclonal antibody received.

Anti-spike monoclonal antibodies were distributed to infusion facilities on behalf of the US government. The specific monoclonal antibody administered to any eligible patient was J o u r n a l P r e -p r o o f based solely on the available product at the infusion facility during the date of treatment. There were no clinical criteria to favor one product over another. The products available during this study were bamlanivimab-etesevimab (700-mg / 1400-mg dose, as a one-time infusion) and casirivimab-imdevimab (1200-mg / 1200-mg dose until June 4, 2021, when the authorized dose was reduced to 600-mg / 600-mg dose, as a one-time infusion) 4,5 . Both monoclonal antibodies were available in all infusion facilities.

Patients were eligible to receive anti-spike monoclonal antibodies if they had mild to moderate COVID-19, confirmed by a positive SARS-CoV-2 PCR or antigen test, and were within 10 days of symptom onset. In addition, patients had at least one of the following criteria: age For the purpose of this study, we used MASS as the measure of high-risk characteristics since this was the comorbidity measure used for the majority of the study period. In addition, we correlated the outcomes with Charlson Comorbidity Index as another measure of medical complexity.

The primary outcome of interest was the proportion of patients with severe outcomes by day 30 after anti-spike monoclonal antibody infusion 12 . We defined severe outcomes in this study according to the WHO Ordinal Scale of 4 (hospitalized and oxygen supplementation by mask or nasal prongs) or greater 12 .

This study was conducted in accordance with the aim of the Strengthening Research of Observational Epidemiologic Studies (STROBE) 13 . The Mayo Clinic Institutional Review Board approved this study. Informed consent was waived. Only patients with research authorization were included.

The baseline characteristics and outcomes of patients who received infusions with bamlanivimab-etesevimab or casirivimab-imdevimab were compared using standard descriptive statistics. Outcomes were compared across groups using a Kruskal-Wallis test.

Unadjusted and adjusted logistic regression models were created to estimate the odds ratio (OR) of severe outcome with infusion of casirivimab-imdevimab compared to bamlanivimabetesevimab. The adjusted odds ratio was calculated by adding Charlson comorbidity index to the regression. This adjustment was performed as a sensitivity analysis to assess the possibility of this index impacting the findings (and was not an exercise in model derivation). Analyses were performed using RStudio version 1.4.1106 (PBC, Boston, MA) and the packages 'dplyr', 14 'epitools' 15 , 'sjplot' 16 and 'ggplot2' 17 . In addition, we conducted a sensitivity analysis calculating adjusted odds to adjust risk of severe outcome for comorbidities.

The study population consisted of 681 patients with mild to moderate COVID-19 who received treatment with bamlanivimab-etesevimab (n=500) or casirivimab-imdevimab (n=181) during February 9, 2021 -June 25, 2021 (a period prior to the SARS-CoV-2 Delta surge in our communities 

The two treatment cohorts were comparable in terms of age, sex, body mass index, race, and ethnicity. Risk factors for severe COVID-19 were comparable between the two cohorts, as assessed by several measures including the Charlson Comorbidity Index. The FDA EUA eligibility criteria, as measured by MASS, was also comparable between the two treatment cohorts. There were no significant differences in the individual components of MASS; the proportion of patients with cardiovascular disease, chronic kidney disease, diabetes mellitus, hypertension, and pulmonary disease were not significantly different between the two cohorts.

Likewise, the proportion of patients with immunocompromised status was not significantly different between the two cohorts ( Table 1) . However, COVID-19 vaccination was significantly higher among patients who received casirivimab-imdevimab. The median time to anti-spike monoclonal antibody infusion was similar between the two cohorts (median of 2 days; range 1-9 days from the time of positive SARS-CoV-2 PCR). All patients were infused within the 10-day period since the onset of symptoms.

Twenty-five of 681 patients (3.7%) developed the primary outcome (had a score of 4 or higher on the WHO ordinal scale for clinical improvement) 12 by day 30 after the monoclonal antibody infusion ( Table 2 ). The primary outcome was significantly higher among 181 patients treated with casirivimab-imdevimab when compared to the 500 patients who received bamlanivimab-etesevimab (6.7% vs. 2.6%, p=0.01). Casirivimab-imdevimab was associated with higher odds of severe outcomes when compared to bamlanivimab-etesevimab (OR: 2.67, 95% confidence interval, 1.17-6.06).

To further investigate the difference in the overall outcomes between the two cohorts, a subgroup analysis was performed on 172 patients residing in Olmsted and Blue Earth counties served predominantly by the Mayo Clinic. The 172 patients were selected in this subgroup analysis since they would be less likely to seek care outside our hospital system. The demographic and clinical characteristics were comparable for 117 patients treated with bamlanivimab-etesevimab and 55 patients treated with casirivimab-imdevimab (Supplementary Table) . By day 30 after monoclonal antibody infusion, severe outcome was Wisconsin, in addition to the wild-type virus, during the time of this study. Bamlanivimabetesevimab and casirivimab-imdevimab were considered similarly effective for treatment of these variants. 2, 4 However, a head-to-head comparison between bamlanivimab-etesevimab and casirivimab-imdevimab has not been performed. Because both antibody products were available for use without clinical criteria that would favor one product over another, comparing the outcomes of the treated patients during the study period could provide insights into their clinical efficacy. 9

In this retrospective study, the overall rate of severe outcomes was 3.7%, and this overall rate is comparable to our previous observations. 10 However, the rate of severe outcome was significantly higher among patients who received casirivimab-imdevimab when compared to bamlanivimab-etesevimab. This significant difference in outcome between the two products was a surprising finding, since pseudovirus experiments have suggested that they should be similarly effective against variants that were circulating in our communities during the study period. 18 This significant difference is unexpected considering that the cohort of patients who received casirivimab-imdevimab had higher COVID-19 vaccination rates. While the reason behind this significant difference in clinical outcomes between bamlanivimab-etsevimab and casirivimab-imdevimab is not clearly apparent, it emphasizes the importance of comparing their efficacy in real-world practice in order to guide their clinical use.

In a prior study, we observed that the risk of hospitalization after monoclonal antibody therapy is influenced by number of medical comorbidities. 10 Hospitalizations was higher among those with multiple medical comorbidities. However, this could not account for the difference in the outcomes in this study. There was no apparent imbalance in the risk factor profiles between the two treatment cohorts. The two groups were not significantly different in terms of age, body mass index, sex, Charlson Comorbidity Index and MASS. The individual components of MASS such as diabetes, obesity, cardiovascular disease, and lung diseases were also not significantly different between the two cohorts.

Despite the differences in clinical outcomes, we believe that casirivimab-imdevimab remains effective in reducing the risk of severe outcomes and hospitalization. In a prior study, J o u r n a l P r e -p r o o f casirivimab-imdevimab reduced the rate of hospitalization compared to propensity-matched untreated cohort. 8 Another retrospective study observed that the 28-day hospitalization was not significantly different between patients treated with casirivimab-imdevimab and those who received bamlanivimab monotherapy. 10 Thus, the underlying reason behind this significant difference in clinical outcomes between casirivimab-imdevimab and bamlanivimab-etesevimab therapies in the current study deserves further investigation.

The limitation of this study is its retrospective study design, and some clinical outcomes may not have been fully captured. This is counterbalanced by the close follow-up of our highrisk patients using the remote monitoring program. 19 In addition, subgroup analysis of patients who resided in Olmsted and Blue Earth counties (who are more likely to seek subsequent care in Mayo Clinic hospitals) reflected the overall outcomes of the full cohort. Second, our program did not randomly allocate the two monoclonal antibody products because we were dependent on available supply allocated from the US government. Moreover, bamlanivimab -etesevimab was only available and infused during a part of the study period (as its distribution was affected by federal allocation), while casirivimab-imdevimab was available throughout the study period.

Despite this lack of randomization, however, the EUA criteria allowed for a highly comparable demographic and clinical characteristics between the two treatment groups. Third, this study is limited by the imbalance in the total number of patients between the two treatment cohorts, with only 181 patients treated with casirivimab-imdevimab. Due to the small denominator of patients treated with casirivimab-imdevimab, the proportion of severe outcomes may have significantly skewed by even a few events. Indeed, this limitation could potentially account for J o u r n a l P r e -p r o o f the significant difference in the study outcomes between the two cohorts. It is therefore suggested that larger patient cohorts be included in future studies to either confirm or refute our observations. Future studies should also include a more diverse cohort, especially underrepresented populations who have been reported to have higher rates of severe outcomes. Finally, our findings reflect only the period dominated by the SARS-CoV-2 wild-type and alpha variants, and may not represent the efficacy of these antibodies against the SARS-CoV-2 Delta (B.1.617 lineage), which has emerged as the predominant variant circulating in our communities, when the analysis for this study was conducted in October 2021. 20 Casirivimabimdevimab and bamlanivimab-etesevimab are reported to be similarly effective against the Delta variant in experimental studies. Whether bamlanivimab-etesevimab also outperforms casirivimab-imdevimab in the era of Delta remains to be seen in the clinical setting.

As anti-spike monoclonal antibodies have emerged as highly effective treatment of mild to moderate COVID-19 among high-risk patients. Our retrospective study demonstrates that while both treatments are associated with low rates of severe disease progression, balmanivimabetesevimab was significantly associated with better clinical outcome compared to casirivimabimdevimab. At the time of this report, SARS-CoV-2 Omicron variant has replaced Delta as the circulating variant of concern in our communities. Balmanivimab-etesevimab and casirivimab- 

An EUA for Bamlanivimab-A monoclonal antibody for COVID-19

SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with Covid-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab

Casirivimab-Imdevimab Treatment is Associated with Reduced Rates of Hospitalization among High-Risk Patients with Mild to Moderate Coronavirus Disease-19

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

Management of C-i. A minimal common outcome measure set for COVID-19 clinical research

The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

dplyr: A Grammar of Data Manipulation

epitools: Epidemiology Tools. 2020

Data Visualization for Statistics in Social Science

Elegant Graphics for Data Analysis

Managing patients in the COVID-19 pandemic: A virtual multidisciplinary approach

COVID data tracker: Variant proportions